Literature DB >> 19787560

Management strategies for optimal control of anticoagulation in patients with atrial fibrillation.

Marcel Levi1, Olaf R de Peuter, Pieter W Kamphuisen.   

Abstract

Most patients with atrial fibrillation need anticoagulant treatment with vitamin K antagonists for prevention of thromboembolism, in particular ischemic stroke. Many studies show the efficacy of this treatment but also that it is difficult to keep patients who use vitamin K antagonists in the proper treatment range. Both a too low and a too high intensity of anticoagulation significantly increase the risk of adverse events. Hence repeated monitoring of the intensity of anticoagulation and dose adjustments are required. Management strategies that improve the time in the therapeutic target range are computer-assisted dosing algorithms and centralized care in anticoagulation clinics. In addition, self-testing of the international normalized ratio and self-dosing of vitamin K antagonists has been introduced over the past 20 years and has been shown to be an effective and safe treatment modality. Thieme Medical Publishers.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19787560     DOI: 10.1055/s-0029-1240016

Source DB:  PubMed          Journal:  Semin Thromb Hemost        ISSN: 0094-6176            Impact factor:   4.180


  4 in total

1.  [New oral anticoagulants: who really needs them?].

Authors:  H K Berthold
Journal:  Internist (Berl)       Date:  2014-01       Impact factor: 0.743

Review 2.  Modern role for clopidogrel in management of atrial fibrillation and stroke reduction.

Authors:  Lars Maegdefessel; Junya Azuma; Philip S Tsao
Journal:  Vasc Health Risk Manag       Date:  2010-03-03

Review 3.  New options with dabigatran etexilate in anticoagulant therapy.

Authors:  Lars Maegdefessel; Joshua M Spin; Junya Azuma; Philip S Tsao
Journal:  Vasc Health Risk Manag       Date:  2010-05-25

4.  Effects of computer-assisted oral anticoagulant therapy.

Authors:  Rune Skovgaard Rasmussen; Pernille Corell; Poul Madsen; Karsten Overgaard
Journal:  Thromb J       Date:  2012-08-30
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.